Shares in French drugmaker Sanofi (SNY) sickened today as trial data on a new eczema treatment disappointed investors.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and… [2366 chars]
Sanofi Stock (SNY) Crashes 9% after Eczema Drug Trial Data Disappoints
